Hanna Nurmi
Overview
Explore the profile of Hanna Nurmi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saari E, Mononen M, Hasala H, Nurmi H, Kettunen H, Suoranta S, et al.
BMC Pulm Med
. 2024 Aug;
24(1):427.
PMID: 39210302
Background: Interstitial lung diseases (ILD) include a wide range of diseases impacting lung parenchyma and leading to fibrosis and architectural distortion. Chronic cough and dyspnea are common symptoms which affect...
2.
Saari E, Mononen M, Hasala H, Latti A, Kaulamo J, Nurmi H, et al.
BMC Pulm Med
. 2023 May;
23(1):179.
PMID: 37221535
Background: Most patients with idiopathic pulmonary fibrosis (IPF) complain of cough. IPF-associated cough is widely characterized as dry or non-productive. The aim of this study was to compare chronic cough...
3.
Salonen J, Nurmi H, Hodgson U, Hasala H, Kilpelainen M, Hollmen M, et al.
Eur Clin Respir J
. 2023 Mar;
10(1):2190210.
PMID: 36950471
Multidisciplinary meeting (MDM) is a core element in the diagnosis of interstitial lung diseases (ILD). The aim of the study was to investigate the implementation and key elements related to...
4.
Keskitalo E, Salonen J, Nurmi H, Vahanikkila H, Kaarteenaho R
J Occup Environ Med
. 2023 Feb;
65(4):349-353.
PMID: 36728947
Objective: Comorbidities are common and affect the prognosis of patients with interstitial lung diseases, but few previous studies have investigated patients with asbestosis. Methods: We collected comorbidities and death causes...
5.
Mononen M, Saari E, Hasala H, Kettunen H, Suoranta S, Nurmi H, et al.
BMC Pulm Med
. 2022 Aug;
22(1):313.
PMID: 35965320
Background: The disease course of idiopathic pulmonary fibrosis (IPF) is progressive and occasionally, other types of interstitial lung disease (ILD) may progress similarly to IPF. This study aimed to evaluate...
6.
Mononen M, Saari E, Hasala H, Kettunen H, Suoranta S, Nurmi H, et al.
Respir Med
. 2022 Jun;
200:106922.
PMID: 35759888
Background: The use of a transbronchial lung cryobiopsy (TBLC) is increasing as a diagnostic method of interstitial lung diseases (ILD). This study aimed to evaluate risk factors associated with clinically...
7.
Nurmi H, Laaksonen S, Raekallio M, Hanninen L
Vet Anaesth Analg
. 2022 Jun;
49(4):423-428.
PMID: 35659721
Objective: To investigate the pharmacokinetics of orally and intravenously (IV) administered meloxicam in semi-domesticated reindeer (Rangifer tarandus tarandus). Study Design: A crossover design with an 11 day washout period. Animals:...
8.
Nurmi H, Kaarteenaho R
J Thorac Dis
. 2020 Jul;
12(6):3000-3003.
PMID: 32642218
No abstract available.
9.
Karkkainen M, Kettunen H, Nurmi H, Selander T, Purokivi M, Kaarteenaho R
BMC Pulm Med
. 2019 Dec;
19(1):228.
PMID: 31783748
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial pneumonia with an unpredictable course. The aims of this study were to retrospectively re-evaluate a cohort of patients with IPF according...
10.
Karkkainen M, Nurmi H, Kettunen H, Selander T, Purokivi M, Kaarteenaho R
BMC Pulm Med
. 2018 May;
18(1):69.
PMID: 29751748
Background: The most common cause of death of patients with idiopathic pulmonary fibrosis (IPF) has been reported to be the lung disease itself and mortality from IPF appears to be...